Filing search / Entero Therapeutics, Inc. / "Independence"

Search information

Entero Therapeutics, Inc.

Companies

"Independence"

Keywords

SEC filings

Source

Export list of results

Export a CSV file of filings or unique companies (up to first 5,000 results).

Download list of filings Download list of companies

33 results

Newest first Best match first

8-K

EX-10.3

ENTO Entero Therapeutics, Inc.

7 Mar 25

Entry into a Material Definitive Agreement

4:05pm

potentially impair his or her independence as a director of the Company; and that he or she shall promptly notify the Board of any arrangements or agreements

PRER14A

ENTO Entero Therapeutics, Inc.

Preliminary revised proxy

further strengthens the Board’s independence and autonomous oversight of our business and also enhances Board communication and effectiveness. The role … of lead independent director serves as a bridge between the independent directors and management. Director Independence The Board has determined

17 Jun 24

5:23pm

10-K

2023 FY

ENTO Entero Therapeutics, Inc.

Annual report

public accounting firm; discussing with our independent registered public accounting firm the independence of its members from its management … TRANSACTIONS, AND DIRECTOR INDEPENDENCE As of May 12, 2022, Messrs. Sapirstein and Borkowski have entered into waiver agreements with the Company pursuant

29 Mar 24

4:16pm

DEF 14A

ENTO Entero Therapeutics, Inc.

Definitive proxy

independence and autonomous oversight of our business and also enhances Board communication and effectiveness. The role of lead independent director serves … as a bridge between the independent directors and management. Director Independence The Board has determined that all of its members, other than Mr

15 May 23

4:54pm

DEF 14A

ENTO Entero Therapeutics, Inc.

Definitive proxy

believes that the lead independent director further strengthens the Board’s independence and autonomous oversight of our business and also enhances Board … Independence The Board has determined that all of its members, other than Mr. Sapirstein, our President and Chief Executive Officer and Chairman of our

25 Jul 22

5:27pm

PRER14A

9569iij4tgg vnghfv

Preliminary revised proxy

15 Jul 22

4:41pm

PRE 14A

mmnjz wdalvkmw

Preliminary proxy

27 May 22

4:05pm

10-K

75acfz

Annual report

31 Mar 22

5:17pm

424B5

nxekpm2z msyh78fk

1 Mar 22

Prospectus supplement for primary offering

Prospectus supplement

21 Jan 22

4:10pm

DEF 14A

yvytul9d9dz9yy0gvud6

Definitive proxy

19 Nov 21

5:00pm

PRE 14A

w7y03g 77e2viol

Preliminary proxy

9 Nov 21

5:19pm

AzurRx BioPharma Announces $3.0 Million Bought

31 Mar 21

5:26pm

424B3

yhmc4svzadso9km 3c

22 Jan 21

Prospectus supplement

13 Jan 21

5:30pm

7 Aug 20

4:43pm

PRE 14A

j3ze8

Preliminary proxy

24 Jul 20

4:30pm

Filing search / Entero Therapeutics, Inc. / "Independence"

33 results

Top filers

Top filing types

Recent filing years